Last edition
News about "Idiopathic Pulmonary Fibrosis (IPF) treatment"
EMA Recommends Approval of Jascayd for IPF and Progressive Pulmonary Fibrosis
Jascayd receives positive CHMP recommendation for approval in Europe to treat Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF), addressing major unmet needs in severe and life-threatening lung diseases.
Idiopathic Pulmonary Fibrosis (IPF) Treatment | 25/05/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members